文献速递MDS 与骨髓增殖性肿瘤

真性红细胞增多症后与原发性血小板增多症后骨髓纤维化患者血栓形成的预测:一项1258例患者的研究

Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
PubMed 文献 · Leukemia · 2022-08-30

在MYSEC数据集1258例继发性骨髓纤维化(SMF)患者中,135例(10.7%)在中位随访3.5年(范围1-21.4年)时发生血栓事件,年发生率为2.3%患者/年,静脉事件占三分之二。Cox多变量分析显示,SMF转化时正在接受细胞减灭治疗与3年内血栓绝对风险降低3.3%相关;单变量回归显示传统细胞减灭治疗(主要为羟基脲,HR 0.41,95% CI 0.26-0.65,p=0.0001)和JAK抑制剂(主要为芦可替尼,HR 0.50,95% CI 0.24-1.02,p=0.05)均与较少血栓相关。

要点

  • SMF患者血栓事件发生率为10.7%,年发生率为2.3%患者/年,静脉事件占三分之二。
  • SMF转化时接受细胞减灭治疗与3年内血栓绝对风险降低3.3%相关。
  • 传统细胞减灭治疗(HR 0.41)和JAK抑制剂(HR 0.50)均与较少血栓相关。

核心结论

  • 本研究提示SMF患者血栓事件发生率不低,细胞减灭治疗可能对血栓事件具有保护作用。

研究设计与样本

  • 基于MYSEC数据集1258例继发性骨髓纤维化(SMF)患者的分析,中位随访3.5年(范围1-21.4年)。

主要发现

  • 135例(10.7%)发生血栓事件,年发生率为2.3%患者/年,静脉事件占三分之二。
  • Cox多变量分析(Fine-Gray模型以死亡为竞争风险)显示,SMF转化时接受细胞减灭治疗与3年内血栓绝对风险降低3.3%相关。
  • 单变量回归显示传统细胞减灭治疗(主要为羟基脲)与较少血栓相关(HR 0.41,95% CI 0.26-0.65,p=0.0001)。
  • JAK抑制剂(主要为芦可替尼)与较少血栓相关(HR 0.50,95% CI 0.24-1.02,p=0.05)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of thrombotic events (TEs). Predisposing factors have been identified in essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (primary MF, PMF), while yet not recognized in post PV/ET-MF (known as secondary MF, SMF). Within the 1258 SMF of the MYSEC (MYelofibrosis SECondary to PV and ET) dataset, 135 (10.7%) developed a TE at a median follow-up of 3.5 years (range, 1-21.4), with an incidence of 2.3% patients per year. Venous events accounted for two-thirds of the total. Cox multivariable analysis, supported by Fine-Gray models with death as competitive risk, showed that being on cytoreductive therapy at time of SMF evolution is associated with an absolute risk reduction of thrombosis equal to 3.3% within 3 years. Considering individually cytoreductive therapies, univariate regression model found that both conventional cytoreduction, mainly hydroxyurea, (HR 0.41, 95% CI: 0.26-0.65, p = 0.0001) and JAK inhibitors, mostly ruxolitinib, (HR 0.50, 95% CI: 0.24-1.02, p = 0.05) were associated with fewer thrombosis. Our study informs treating physicians of a non-low incidence of TEs in post PV/ET-MF and of the potential protective role of cytoreductive therapy in terms of thrombotic events.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Mora B, Guglielmelli P, Kuykendall A, et al. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. Leukemia. 2022. PMID: 36042316. doi:10.1038/s41375-022-01673-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。